ArticleFrontiers in neurology2025
Efficacy of acupuncture for Parkinson's disease with mild cognitive impairment: study protocol for a randomized controlled trial.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Acupuncture for Pain in Parkinson's Disease: Study Protocol for a Randomized Controlled Trial.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease with mild cognitive impairment (PD-MCI) is one of the primary non-motor symptoms of Parkinson's disease (PD). PD-MCI represents an early stage of cognitive impairment in PD and serves as a potential precursor to PDD. To date, research on the treatment of mild cognitive impairment in PD remains limited. Acupuncture, a classical therapeutic modality in Traditional Chinese Medicine, exhibits superior therapeutic outcomes to pharmacotherapy for mild cognitive impairment while avoiding drug-associated adverse effects. Objective: This randomized, single-blind clinical trial aims to evaluate the efficacy and safety of acupuncture for PD-MCI. To improve the credibility of acupuncture research evidence through employing a sham acupuncture device as a control. Methods and analysis: This is a prospective, sham-controlled, subject-blinded and assessor-blinded trial, which conducted at a single center in China. A total of 72 eligible PD-MCI volunteers will be randomized using a simple randomization method in a 1:1 ratio into the acupuncture group and the placebo acupuncture group to receive either acupuncture or placebo acupuncture for 20 sessions over a succession of 5 weeks. The primary outcome measure will be the Montreal Cognitive Assessment Scale (MoCA) score. The secondary outcome measures will be the scores of Mini-Mental State Examination (MMSE), Unified Parkinson's Disease Rating Scale Motor Examination (UPDRSIII) and the level of neurofilament light polypeptide (NfL) and glial cell-derived neurotrophic factor (GDNF). The evaluation will be assessed before and after treatment. Discussion: This study represents the first randomized, single-blind clinical trial investigating acupuncture treatment for cognitive dysfunction in Parkinson's disease. An auxiliary device designed by our team, featuring a flat-head needle and adjustable sleeve, will be used for placebo acupuncture procedure to achieve a single-blind effect. Serum NfL and GDNF levels will be incorporated to elucidate the mechanisms underlying acupuncture's effects and explore specific biomarkers of PD. The aim of this study is to provide reliable clinical evidence for the treatment of PD-MCI and improve patients' survival and quality of life. Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2400082082.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.